THIS KNOWVEMBER, IT IS TIME TO #knowDPN
KNOWvember 2024
Each November, the U.S. Pain Foundation highlights a different pain-related topic. This year, our focus is on diabetic nerve pain, also known as diabetic peripheral neuropathy (DPN), through our initiative, #knowDPN. This campaign aims to raise awareness about the seriousness of diabetes-related pain, highlight the importance of early detection, and guide individuals on accessing specialized care and treatment options to improve health outcomes.
Throughout the month, we’ll share key facts on diabetes-related pain across Facebook, Twitter, and Instagram. Our resources will include an infographic on essential foot care for those with DPN and two informative articles—one emphasizing the value of early detection and preventive measures and the other debunking common myths about diabetic nerve pain. Additionally, we’ll host a webinar focused on understanding DPN’s diagnosis and management and three interactive online events to dive into DPN’s impact, available educational resources, and insights from individuals with lived experience.
On this page, you’ll find all the information you need to become involved this KNOWvember with #knowDPN.
WAYS TO GET INVOLVED
There are MANY easy ways you can help share the information you learn this KNOWvember with others, such as:
- Download our infographic or order your own print copy.
- Like, comment, and share/retweet our posts on social media.
- Use the hashtags, #knowDPN and #KNOWvember, in all your social media posts in November.
- Read and share articles.
- Register and attend our webinar.
- Register and join our online events.
Articles
Get to #knowDPN this KNOWvember
The complications associated with diabetes are numerous—and overwhelming. But in the flurry of managing diabetes and its potential comorbidities and symptoms, one is often forgotten: nerve damage and pain. Diabetic peripheral neuropathy (DPN),...
upcoming webinar
Navigating the Diagnosis and Management of Diabetic Nerve Pain
Join us for a webinar to better understand diabetic peripheral neuropathy (DPN). Learn about the diagnostic processes, various management options, and current and emerging treatments. Additionally, we’ll look at the future of DPN research and ongoing clinical trials that could transform treatment. REGISTER TODAY.
NEW RESOURCE FOR YOU
Want to learn tips to effective foot care? Check out this infographic.
join an online event this KNOWvember
Get to KNOW DPN: A Health Hack Event
Get to KNOW the INvisible Project: Diabetes Edition
Get to KNOW the Lived DPN Experience
U.S. Pain Foundation collaborated with Humana Neighborhood Centers to create a series of Health Hack videos exploring various aspects of chronic pain. One highlights diabetic peripheral neuropathy. Register now to watch this informative Health Hack on November 7 at 12 p.m. ET!
Earlier this year, U.S. Pain published its latest INvisible Project magazine sharing the experiences of those living with diabetes-related pain. Join us live on November 25 at 12 p.m. ET to learn more about this edition, explore resources about DPN, and find out how to order free copies.
You spoke, and we listened! Join us on November 30 at 12 p.m. ET to hear from indivduals living with diabetic peripheral neuropathy (DPN). Hear about their challenges, daily struggles, and hopes for the future. Together, we can share our stories and gain valuable insights into the experience of DPN.
Social Media Fact Sources
- Fact: Diabetic peripheral neuropathy (DPN) is a disease experienced by those living with diabetes caused by high blood sugar that damages the nerves, most often in the feet. It can lead to loss of sensation and pain, as well as undetected injuries and the need for amputations. | Source
- Fact: Diabetic peripheral neuropathy (DPN) can affect as many as 50% of people living with diabetes. |
Source - Fact: A team supported by the NIH HEAL initiative is exploring a treatment that would treat DPN by targeting its source: hyperactive nerve cells.| Source
THANK YOU TO OUR SPONSORS
Our 2024 KNOWvember campaign is made possible through contributions from Averitas and Vertex Pharmaceuticals.
